Asenapine

General information

Indicated for: Schizophrenia; acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy or adjunct).

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: 5–10 mg SL BID

Mechanism (brief)

Antagonist at D2/D3 and 5‑HT2A receptors with additional α1 and H1 blockade.

Metabolism & Half‑life

• Metabolism: UGT1A4 glucuronidation and CYP1A2 oxidation.
• Half‑life: ~24 h (sublingual); ~30 h (transdermal).

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually
• Orthostatic blood pressure — During titration
• Dermatologic check (patch) — Each visit

Sources

• Asenapine label — DailyMed (2025)